{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.071","value":"8.72"},{"groupId":"OG001","spread":"19.932","value":"8.20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer participants. Participant's responses to 2 questions (Items 29+30: \"How would you rate your overall health during the past week?\" and \"How would you rate your overall quality of life during the past week?\") are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall outcome. Change from baseline to Cycle 12 Day 1 as presented.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were randomized to sabatolimab plus Azacitidine","id":"OG000","title":"Sabatolimab (MBG453) + Azacitidine"},{"description":"Participants were randomized to placebo plus Azacitidine","id":"OG001","title":"Placebo + Azacitidine"}],"paramType":"MEAN","populationDescription":"FAS population with non-missing baseline (Cycle 1 Day 1) and Cycle 12 Day 1 EORTC-QLQ-C30 assessments. FAS comprised of all patients to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"Up to Cycle 12 Day 1 (C12D1) (1 cycle = 28 days)","title":"Change From Baseline of Global Health Status/Quality of Life Scores Using European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC-QLQ-C30).","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}